Imprimis
4 federal recalls on file. We monitor every CPSC, FDA, USDA, and NHTSA notice for Imprimis and translate it into plain English — free weekly digest, optional same-day alerts.
- 2026-01-14FDA-DrugClass IIStop using Imprimis Tri-Moxi eye injections
Imprimis NJOF recalled Tri-Moxi+ eye injections because some batches contain glass-like particles. The affected batches (25JAN033A and 25JAN033B) expire in February 2026. No injuries have been reported.
- 2026-01-14FDA-DrugClass IIStop using Imprimis NJOF eye injection
Imprimis NJOF's dexamethasone-moxifloxacin-ketorolac eye injection contains glass-like particles that could contaminate the injection. This medication is used during eye surgery. The affected lots are 25APR001A and 25APR001B, expiring 04/03/2026.
- 2026-01-14FDA-DrugClass IIStop using Imprimis eye injection immediately
Imprimis NJOF, LLC is recalling specific lots of Dexamethasone Moxifloxacin intraocular injection due to the presence of glass-like particles in the medication. This injection is used during eye surgery. Two affected lots have been identified and distributed nationwide.
- 2025-11-26FDA-DrugClass IIIKlarity-C Drops (Cyclosporine) 0.1%, Preservative-Free Sterile Ophthalmic Emulsion, This is a compounded drug, Office Use Only, 5.5 mL bottle, Rx only, Mfg by: Imprimis NJOF, LLC, 1705 Route 46 West, Ledgewood, NJ 07852, NDC 71384-514-05
Subpotent Drug
Get notified about new Imprimis recalls
Free weekly digest. We email when a new federal recall affects Imprimis or anything else in your household.
Get the Sunday Brief